Aclaris Therapeutics Stock Net Asset
| ACRS Stock | USD 1.93 0.02 1.05% |
Fundamental analysis of Aclaris Therapeutics allows traders to better anticipate movements in Aclaris Therapeutics' stock price by examining its financial health and performance throughout various phases of its business cycle.
Aclaris | Net Asset | Build AI portfolio with Aclaris Stock |
Aclaris Therapeutics Company Net Asset Analysis
Aclaris Therapeutics' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Aclaris Therapeutics Net Asset | 220.33 M |
Most of Aclaris Therapeutics' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aclaris Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Aclaris Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Aclaris Therapeutics is extremely important. It helps to project a fair market value of Aclaris Stock properly, considering its historical fundamentals such as Net Asset. Since Aclaris Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Aclaris Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Aclaris Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Aclaris Total Assets
Total Assets |
|
Based on the recorded statements, Aclaris Therapeutics has a Net Asset of 220.33 M. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Aclaris Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aclaris Therapeutics' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aclaris Therapeutics could also be used in its relative valuation, which is a method of valuing Aclaris Therapeutics by comparing valuation metrics of similar companies.Aclaris Therapeutics is currently under evaluation in net asset category among its peers.
Aclaris Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Aclaris Therapeutics from analyzing Aclaris Therapeutics' financial statements. These drivers represent accounts that assess Aclaris Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Aclaris Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 78.1M | 275.2M | 824.9M | 73.3M | 191.7M | 182.1M | |
| Enterprise Value | 42.8M | 267.3M | 800.4M | 36.9M | 169.7M | 161.2M |
Aclaris Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Aclaris Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Aclaris Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Aclaris Therapeutics' value.| Shares | Marshall Wace Asset Management Ltd | 2025-06-30 | 2.3 M | Logos Global Management Lp | 2025-06-30 | 1.9 M | Renaissance Technologies Corp | 2025-06-30 | 1.5 M | Palo Alto Investors, Llc | 2025-06-30 | 1.4 M | Bollard Group Llc | 2025-06-30 | 1.4 M | Citadel Advisors Llc | 2025-06-30 | 1.1 M | State Street Corp | 2025-06-30 | 1 M | Deutsche Bank Ag | 2025-06-30 | 1 M | Aldebaran Capital Llc | 2025-06-30 | 993.7 K | Bml Capital Management Llc | 2025-06-30 | 14.2 M | Adage Capital Partners Gp Llc | 2025-06-30 | 9.6 M |
Aclaris Fundamentals
| Return On Equity | -1.01 | ||||
| Return On Asset | -0.21 | ||||
| Operating Margin | (9.51) % | ||||
| Current Valuation | 90.4 M | ||||
| Shares Outstanding | 108.33 M | ||||
| Shares Owned By Insiders | 2.68 % | ||||
| Shares Owned By Institutions | 86.23 % | ||||
| Number Of Shares Shorted | 5.92 M | ||||
| Price To Earning | (12.14) X | ||||
| Price To Book | 1.59 X | ||||
| Price To Sales | 12.45 X | ||||
| Revenue | 18.72 M | ||||
| Gross Profit | (36.3 M) | ||||
| EBITDA | (51.72 M) | ||||
| Net Income | (132.06 M) | ||||
| Cash And Equivalents | 248.6 M | ||||
| Cash Per Share | 3.73 X | ||||
| Total Debt | 2.6 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 15.99 X | ||||
| Book Value Per Share | 1.22 X | ||||
| Cash Flow From Operations | (20.07 M) | ||||
| Short Ratio | 4.65 X | ||||
| Earnings Per Share | (1.57) X | ||||
| Price To Earnings To Growth | (0.13) X | ||||
| Target Price | 7.86 | ||||
| Number Of Employees | 61 | ||||
| Beta | 0.29 | ||||
| Market Capitalization | 209.08 M | ||||
| Total Asset | 220.33 M | ||||
| Retained Earnings | (902.86 M) | ||||
| Working Capital | 94.36 M | ||||
| Current Asset | 86.52 M | ||||
| Current Liabilities | 1.55 M | ||||
| Net Asset | 220.33 M |
About Aclaris Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aclaris Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aclaris Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aclaris Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aclaris Stock Analysis
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.